Shanghai HeartCare Medical Technology Corp Ltd
HKEX:6609
Net Margin
Shanghai HeartCare Medical Technology Corp Ltd
Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.
Net Margin Across Competitors
| Country | Company | Market Cap |
Net Margin |
||
|---|---|---|---|---|---|
| CN |
|
Shanghai HeartCare Medical Technology Corp Ltd
HKEX:6609
|
1.1B HKD |
-5%
|
|
| US |
|
Abbott Laboratories
NYSE:ABT
|
229.5B USD |
32%
|
|
| US |
|
Intuitive Surgical Inc
NASDAQ:ISRG
|
199.1B USD |
28%
|
|
| US |
|
Boston Scientific Corp
NYSE:BSX
|
155.1B USD |
12%
|
|
| US |
|
Stryker Corp
NYSE:SYK
|
145.6B USD |
12%
|
|
| IE |
|
Medtronic PLC
NYSE:MDT
|
104.5B USD |
14%
|
|
| DE |
|
Siemens Healthineers AG
XETRA:SHL
|
53.1B EUR |
9%
|
|
| US |
|
Becton Dickinson and Co
NYSE:BDX
|
49.8B USD |
7%
|
|
| US |
|
Edwards Lifesciences Corp
NYSE:EW
|
45.5B USD |
75%
|
|
| US |
|
IDEXX Laboratories Inc
NASDAQ:IDXX
|
41.6B USD |
23%
|
|
| CN |
|
Shenzhen Mindray Bio-Medical Electronics Co Ltd
SZSE:300760
|
279.5B CNY |
31%
|
Shanghai HeartCare Medical Technology Corp Ltd
Glance View
Shanghai Heartcare Medical Technology Corp. Ltd. engages in the research, development, manufacture, and sale of neuro-interventional medical devices. The company is headquartered in Shanghai, Shanghai. The company went IPO on 2021-08-20. The firm's product portfolio includes both neuro-interventional and cardiac medical devices, and its main products are CaptorTM thrombectomy device (Captor) and left atrial appendage occluder. The firm's product portfolio extends from the treatment and prevention of ischemic stroke, including acute ischemic stroke and intracranial stenosis to the treatment of hemorrhagic stroke. The firm's other products include the balloon guiding catheter, the ExtraFlex distal access catheter and SupSelek microcatheter. The firm distributes its products within the domestic market.
See Also
Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.
Based on Shanghai HeartCare Medical Technology Corp Ltd's most recent financial statements, the company has Net Margin of -4.9%.
You don't have any saved screeners yet